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There is extensive debate on the neurological consequences of corona virus disease 2019 (COVID‐19) and the impact this might have for patients with neurodegenerative conditions, including Parkinson\'s disease (PD). Older advanced PD patients may represent a particularly vulnerable population, as respiratory muscle rigidity as well as impairment of cough reflex alongside preexisting dyspnoea may lead to increased severity of COVID‐19.[^1^](#mds28104-bib-0001){ref-type="ref"} In addition, there are indirect possible effects, such as the impact of stress, self‐isolation, and anxiety, as well as the consequences of prolonged immobility because of the lockdown.[2](#mds28104-bib-0002){ref-type="ref"}, [3](#mds28104-bib-0003){ref-type="ref"}

Several observations make the link between COVID‐19 and PD particularly intriguing. Antibodies against coronavirus were found in the cerebrospinal fluid of PD patients more than 2 decades ago, suggesting a possible role for viral infections in neurodegeneration.[^4^](#mds28104-bib-0004){ref-type="ref"} Angiotensin‐converting enzyme 2 (ACE2) receptors are highly expressed in dopamine neurons, and they are reduced in PD because of the degenerative process; therefore, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)--related brain penetration may cause additional harm and worsen symptoms and may increase the requirement of dopamine replacement therapy, as evident in 5 of our cases.[5](#mds28104-bib-0005){ref-type="ref"}, [6](#mds28104-bib-0006){ref-type="ref"} Interestingly, the ability of coronaviruses to enter the brain through the nasal cavity determines anosmia/hyposmia and ageusia in many infected subjects, a symptomatology that closely resembles one of the most prominent premotor symptom of PD.[^7^](#mds28104-bib-0007){ref-type="ref"} Finally, the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID‐19, as ACE2 and dopamine decarboxylase coexpress and coregulate in nonneuronal cell types, which may indicate dopamine depletion and the need for considering levodopa as treatment.[^8^](#mds28104-bib-0008){ref-type="ref"}

Outcomes of PD patients infected by SARS‐CoV‐2 are unknown. We present here the outcome of 10 clinical cases (Table [1](#mds28104-tbl-0001){ref-type="table"}) collected from the experience at the Parkinson and Movement Disorders Unit in Padua, Italy, and the Parkinson\'s Foundation Centre of Excellence at King\'s College Hospital in London, UK, from the beginning of March to the current period. The PD center in Padua has a catchment of 1022 patients, mainly in the province of Padua, which had 3407 cases of COVID‐19, 2 of whom were advanced PD patients. Both were women residing in nursing homes with severe motor manifestations, and both were treated with levodopa therapy (Table [1](#mds28104-tbl-0001){ref-type="table"}). One remained asymptomatic, whereas the other, who in the last months had been suffering from deteriorating cognition and hallucinations, developed respiratory problems and died. The King\'s center has 4000 PD patients in the catchment and is currently following more than 600 patients. In all, thus far, 8 cases have been identified with COVID‐19, and clinical details are presented here. The Kings\' COVID‐19 PD group consists of 6 men and 2 women, all older than 60 years of age with severe motor dysfunction, comorbidities, and most requiring additional levodopa dosing following infection (Table [1](#mds28104-tbl-0001){ref-type="table"}). Anxiety and other nonmotor features, such as fatigue, orthostatic hypotension, cognitive impairment, and psychosis, also worsened during the infection. Fatigue was a dominant symptom during the SARS‐CoV‐2 infection in all cases on advanced therapies. Three patients died from COVID‐19 pneumonia.

###### 

Clinical features and outcomes of Parkinson\'s disease patients with corona virus disease 2019.

  Patients   Age   Sex   PD duration (years)   PD therapy                                                                                                                                                                                                                                            Comorbidities                                                                                                     Clinical picture requiring SARS‐CoV‐2 testing                                         Therapeutic interventions(antibiotics and intensive care)                                                                                                                 Outcome
  ---------- ----- ----- --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  1          76    F     28                    Carbidopa‐levodopa 25/100 mg 1 table t 3 times daily and ½ tablet once dailyRotigotine 4 mg 1 patch once dailySafinamide 50 mg 1 tablet once daily                                                                                                    DementiaDysphagiaSevere joint deformities                                                                         Fever                                                                                 No intensive care required                                                                                                                                                Spontaneous recovery
  2          79    F     12                    Carbidopa‐levodopa 25/100 mg 1½ tablets 4 times daily                                                                                                                                                                                                 DementiaHallucinations                                                                                            FeverCoughShortness of breathConfusion                                                CPAP required (no resuscitation was advised)                                                                                                                              Died 14 days after onset of respiratory symptoms
  3          81    M     10                    Carbidopa‐Levodopa CR 25/100 mg 1 tablet once dailyCarbidopa‐Levodopa 25/100 mg 2 tab 3 times daily                                                                                                                                                   HypertensionIschemic heart diseaseChronic kidney diseaseDementia                                                  FeverDry coughShortness of breath                                                     Antibiotics (piperacillin/tazobactam + clarithromycin)No intensive care or CPAP requiredRequired increased levodopa dosing                                                Transferred to rehabilitation ward after 11 days of hospitalization
  4          94    M     2                     Carbidopa‐Levodopa 25/100 mg 1 tablet 3 times daily                                                                                                                                                                                                   Angina pectorisOsteoporosis                                                                                       Multiple falls and head injuryCoughDeliriumArrhythmia                                 Antibiotics (amoxicillin/clavulanic acid + clarithromycin)No intensive care or CPAP required                                                                              Transferred to rehabilitation ward for respite care; 10 days of hospitalisation
  5          87    M     6                     Carbidopa‐Levodopa 25/100 mg 1 tablet twice dailyCarbidopa‐Levodopa 25/100 mg 1½ tablets twice daily                                                                                                                                                  Congestive Cardiac failureChronic obstructive pulmonary diseaseAtrial fibrillationOrthostatic hypotensionAsthma   Syncopal episodesHallucinationsFall with facial traumaCough                           Antibiotics (amoxicillin/clavulanic acid)No intensive care, CPAP not possible because of facial trauma (no resuscitation was advised)Required increased levodopa dosing   Died after 10 days of hospitalization
  6          83    F     3                     Carbidopa‐Levodopa 25/100 mg 2 tablets twice daily and 1½ tablets twice daily                                                                                                                                                                         Anxiety disorder                                                                                                  Worsening of mobility with fall and hyperCKemiaDry coughFatigueWorsening of anxiety   No intensive care or CPAP requiredRequired increase in levodopa dosing                                                                                                    Transferred to neurorehabilitation after 25 days of hospitalization
  7          61    M     17                    IJLI 1684 mg dailyCarbidopa‐levodopa 25/100 mg 1 tablet once dailyRotigotine 4 mg 1 patch once dailyOpicapone 50 mg 1 tablet once daily                                                                                                               Traumatic fractures secondary to fallsOrthostatic hypotension                                                     FeverCoughFatigue                                                                     AntibioticsCPAP required                                                                                                                                                  Died during hospitalization
  8          75    M     10                    IJLI 1262 mg dailyOpicapone 50 mg 1 tablet once dailyCarbidopa‐Levodopa CR 50/200 mg 1 tablet once dailyCarbidopa‐Levodopa CR 25/100 mg 1 tablet once dailyLevodopa‐ Benserazide 100/50 mg 1 tablet 3 times daily                                     Orthostatic hypotensionOsteoporosisBenign prostatic hyperplasiaDepressionNeuropathic pain                         FeverCoughFatigue                                                                     AntibioticsCPAP required                                                                                                                                                  Died during hospitalization
  9          72    M     15                    DBS bilateral STNSubcutaneous Apomorphine infusion 46 mg dailyRasagiline 1 mg 1 tablet once dailyRopirinole CR 2 mg 1 tablet once dailyLevodopa‐benserazide 50/12.5 mg 1 tablet 4 times dailyCarbidopa‐Levodopa CR 25/100 mg 1 tablet 3 times daily   AsthmaDiabetes mellitus type II                                                                                   FeverFatigueWorsening of motor symptoms                                               Required increase in levodopa dosingNo intensive care or CPAP required                                                                                                    Spontaneous recovery, waiting for transfer for rehabilitation
  10         75    F     24                    IJLI stopped due to recent PEG‐J tube malfunctioningLevodopa‐Benserazide 100/25 mg six times dailyCarbidopa‐Levodopa CR 25/100 mg once daily                                                                                                          Atrial fibrillationCognitive impairment                                                                           FatigueCough                                                                          Required increase in levodopa dosingNo intensive care or CPAP required                                                                                                    Recovering

CPAP, continuous positive airway pressure; CR, controlled release; DBS, deep brain stimulation; IJLI, intrajejunal levodopa infusion; F, female; M, male; PD, Parkinson\'s disease; PEG‐J, percutaneous endoscopic transgastric jejunostomy; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; STN, subthalamic nucleus.

These findings suggest that PD patients of older age (mean, 78.3 years) with longer disease duration (mean, 12.7 years) are particularly susceptible to COVID‐19 with a substantially high mortality rate (40%). Those on advanced therapies, such as deep brain stimulation or levodopa infusion therapy, seem especially vulnerable, and a mortality rate of 50% among our 4 such cases is of concern. Although 2 recent articles have addressed the issue of COVID‐19 in PD, none specifically showed cases directly affected by COVID‐19, and we believe ours is the first report of this nature.[2](#mds28104-bib-0002){ref-type="ref"}, [3](#mds28104-bib-0003){ref-type="ref"} The report of Prasad et al focuses on the perceptions of SARS‐CoV‐2 infection in 100 PD patients and some symptoms listed tally with our observations in a real‐life population with COVID‐19.[^2^](#mds28104-bib-0002){ref-type="ref"} Many national and charity guidelines do not list PD or specifically older subjects on advanced therapies as a susceptible group, and this information needs to be amended in light of these new data.[^9^](#mds28104-bib-0009){ref-type="ref"}

Author Roles {#mds28104-sec-0003}
============

Angelo Antonini: conception, data collection, manuscript, review and critique.

Valentina Leta: data collection, review and critique.

James Teo: data collection, review and critique.

K Ray Chaudhuri: conception, data collection, manuscript, review and critique.

Financial Disclosures of all authors (for the preceding 12 months) {#mds28104-sec-0004}
==================================================================

Angelo Antonini has received compensation for consultancy and speaker‐related activities from UCB, Boehringer Ingelheim, AbbVie, Zambon, and Lundbeck; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 ‐ PD_Pal grant 825785, and Ministry of Education University and Research (MIUR) grant ARS01_01081. He serves as consultant for Boehringer--Ingelheim for legal cases on pathological gambling. Valentina Leta reports grants from BRC, Parkinson\'s UK, speaker‐related activities fees from Britannia Pharmaceuticals, and consultancy fees from Invisio Pharmaceuticals, outside the submitted work. James Teo has received research support and funding from InnovateUK, Bristol‐Myers‐Squibb, and iRhythm Technologies and holds shares \< £5000 in Glaxo Smithkline and Biogen. K. Ray Chaudhuri has received honoraria for advisory board from AbbVie, UCB, Pfizer, Jazz Pharma, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, and Scion; hnoraria for lectures from AbbVie, Britannia Pharmaceuticals, UCB, Mundipharma, Zambon, Novartis, Boehringer Ingelheim, Neuroderm, and Sunovion; grants (investigator‐Initiated) from Britannia Pharmaceuticals, AbbVie, UCB, GKC, and Bial; academic grants from IMI EU, Parkinson\'s UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF (USA), and MRC.

The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health. There are no funding sources to disclose. The authors also thank all clinicians and front‐line staff engaged in the care of COVID‐19 patients at King\'s College and Princess Royal Hospitals, London, UK, as well as at the Parkinson and Movement Disorders Unit in Padua, Italy.
